Return to search

Effect of Chinese herbal medicine on drug metabolizing enzyme activities: investigation with extract of Ginkgo biloba leaf (EGb 761).

Sun Huimin. / Thesis submitted in: December 2002. / Thesis (M.Phil.)--Chinese University of Hong Kong, 2003. / Includes bibliographical references (leaves 77-89). / Abstracts in English and Chinese. / TITLE PAGE --- p.i / ACKNOWLEDGEMENTS --- p.ii / ABSTRACT --- p.iii / ABSTRACT IN CHINESE --- p.v / LIST OF PUBLICATIONS --- p.vii / ABBREVIATIONS --- p.viii / TABLE OF CONTENTS --- p.ix / Chapter CHAPTER 1. --- General Introduction --- p.1 / Chapter 1.1 --- Current Status of Herbal Product Use --- p.1 / Chapter 1.2 --- Herb-drug interactions --- p.2 / Chapter 1.2.1. --- Mechanisms of herb-drug interaction --- p.3 / Chapter 1.2.2. --- Pharmacodynamic interaction --- p.3 / Chapter 1.2.3. --- Pharmacokinetic interaction --- p.4 / Chapter 1.2.4. --- Herb-drug interaction involving drug metabolizing enzymes --- p.5 / Chapter 1.3 --- Methodologies for studying herb-drug interactions involving CYP enzymes --- p.7 / Chapter 1.3.1. --- Animal studies (Ex vivo approach) --- p.7 / Chapter 1.3.2. --- In vitro inhibition/induction studies --- p.8 / Chapter 1.3.3. --- Clinical studies --- p.9 / Chapter CHAPTER 2. --- Effect of flavonoid-containing herbs on CYP 450 enzyme activities: a screening study in rat --- p.11 / Chapter 2.1 --- Introduction --- p.11 / Chapter 2.2 --- Materials and Methods --- p.12 / Chapter 2.2.1. --- Chemicals --- p.12 / Chapter 2.2.2. --- Herbs --- p.12 / Chapter 2.2.3. --- Preparation of herbal extracts --- p.13 / Chapter 2.2.3.1. --- Preparation of Green Tea extract --- p.13 / Chapter 2.2.3.2. --- Preparation of Decaffeinated Green Tea (DGT) and its extracts --- p.13 / Chapter 2.2.3.3. --- "Preparation of extracts of Huang Qin, Ge Gen and Huai Mi" --- p.14 / Chapter 2.2.3.4. --- Preparation of Ginkgo biloba extract suspension --- p.14 / Chapter 2.2.4. --- Animal treatment --- p.14 / Chapter 2.2.5. --- Preparation of rat liver microsomes --- p.15 / Chapter 2.2.6. --- Determination of protein content of liver microsomes --- p.16 / Chapter 2.2.7. --- Determination of microsomal CYP content --- p.17 / Chapter 2.2.8. --- Statistical analysis --- p.19 / Chapter 2.3 --- Results --- p.19 / Chapter 2.4 --- Discussion --- p.24 / Chapter 2.5 --- Conclusion --- p.25 / Chapter CHAPTER 3 --- Rationale of the clinical study --- p.26 / Chapter CHAPTER 4 --- Development of HPLC methods for simultaneous determination of multiple probe drugs and their metabolites in human plasma or urine --- p.30 / Chapter 4.1 --- Introduction --- p.30 / Chapter 4.2 --- Materials and Methods --- p.33 / Chapter 4.2.1. --- Chemicals and reagents --- p.33 / Chapter 4.2.2. --- Preparation of stock and working solutions --- p.33 / Chapter 4.2.3. --- Equipment and chromatographic conditions --- p.34 / Chapter 4.2.4. --- Treatment of plasma and urine samples with β-glucuronidase --- p.35 / Chapter 4.2.5. --- Extraction procedures --- p.36 / Chapter 4.2.6. --- Preparation of working solutions for calibration curve --- p.37 / Chapter 4.3 --- Results --- p.39 / Chapter 4.3.1. --- Separation of the analytes --- p.39 / Chapter 4.3.2. --- Calibration and linearity --- p.39 / Chapter 4.3.3. --- Sensitivity --- p.39 / Chapter 4.3.4 --- Accuracy and precision --- p.50 / Chapter 4.4 --- Discussion --- p.52 / Chapter 4.5 --- Conclusions --- p.53 / Chapter CHAPTER 5 --- Stability study of probe drugs --- p.54 / Chapter 5.1 --- Introduction --- p.54 / Chapter 5.2 --- Materials and Methods --- p.54 / Chapter 5.2.1. --- Preparation of standard solutions of probe drugs --- p.54 / Chapter 5.2.2. --- Preparation of stability study mediums --- p.54 / Chapter 5.2.2.1. --- Gastric juice (pH=1.2) --- p.54 / Chapter 5.2.2.2. --- Intestine fluid (pH=6.8) --- p.54 / Chapter 5.2.2.3. --- Human plasma (pH=7.4) --- p.55 / Chapter 5.2.2.4. --- Phosphate buffer (pH=7.4) --- p.55 / Chapter 5.2.3. --- Incubation --- p.55 / Chapter 5.2.4. --- Determination of probe drug concentrations in incubation samples --- p.56 / Chapter 5.3 --- Results --- p.57 / Chapter 5.4 --- Discussion --- p.59 / Chapter 5.5 --- Conclusion --- p.59 / Chapter CHAPTER 6 --- Effect of the extract of Ginkgo biloba leaf (761) on CYP isozymes in human subjects --- p.60 / Chapter 6.1 --- Introduction --- p.60 / Chapter 6.2 --- Materials and Methods --- p.60 / Chapter 6.2.1. --- Drugs --- p.60 / Chapter 6.2.2. --- Subjects --- p.61 / Chapter 6.2.3. --- Study design --- p.62 / Chapter 6.2.4. --- Determination of probe drugs/metabolites in the plasma and urine --- p.63 / Chapter 6.2.5. --- Data analysis --- p.65 / Chapter 6.2.6. --- Statistical analysis --- p.66 / Chapter 6.3 --- Results --- p.66 / Chapter 6.3.1. --- Effect of EGb761on CYP1A2 activity --- p.66 / Chapter 6.3.2. --- Effect of EGb761on CYP2E1 activity --- p.67 / Chapter 6.3.3. --- Effect of EGb761 on CYP450 3A activity --- p.68 / Chapter 6.3.4. --- Effect of EGb761 on NAT2 activity --- p.69 / Chapter 6.3.5. --- Effect of EGb761 on CYP2D6 activity --- p.70 / Chapter 6.3.6. --- Effects of EGb761 on CYP2C19 activity --- p.71 / Chapter 6.4 --- Discussion --- p.72 / Chapter 6.5 --- Conclusion --- p.76 / References --- p.77 / Appendix --- p.90

Identiferoai:union.ndltd.org:cuhk.edu.hk/oai:cuhk-dr:cuhk_324477
Date January 2003
ContributorsSun, Huimin., Chinese University of Hong Kong Graduate School. Division of Pharmacy.
Source SetsThe Chinese University of Hong Kong
LanguageEnglish, Chinese
Detected LanguageEnglish
TypeText, bibliography
Formatprint, xi, 89 leaves : ill. (some col.) ; 30 cm.
RightsUse of this resource is governed by the terms and conditions of the Creative Commons “Attribution-NonCommercial-NoDerivatives 4.0 International” License (http://creativecommons.org/licenses/by-nc-nd/4.0/)

Page generated in 0.0019 seconds